Eli Lilly's $19.3B Quarter Proves the Dip Was Wrong — LLY CFD Leverage Scenarios & GLP-1 Sector Impact

Event Summary

Eli Lilly & Company posted a blockbuster Q4 2025, reporting revenue of $19.3B against consensus expectations of roughly $16–17B — a $3.23B beat representing 43% year-over-year growth. According to Saxo Bank and Investing.com, adjusted EPS came in at $7.54 versus the $7.02 consensus. Mounjaro (tirzepatide, diabetes) generated $6.52B while Zepbound (obesity) added $3.59B, together validating the GLP-1 megatrend. Lilly simultaneously raised 2026 guidance to $63–63.5B in sales and EPS of $23.00–23.70.

A key structural catalyst: the FDA removed tirzepatide from its drug shortage list, signalling supply constraints are easing. Combined with the $15B buyback authorized in December 2024, this positions LLY as part of the broader Q1 Earnings Beat & Outlook Upgrade Wave reshaping healthcare sector valuations in 2026.

Leverage Impact Analysis

LLY is trading at $939.86 (+9.94% on the day, range $850.99–$941.72). For traders using CoinUnited.io's stock CFDs with up to 2000x leverage, the move creates both opportunity and acute liquidation risk.

Worked example — Long CFD: A trader opening a 50x long LLY CFD at $850.99 (day's low) with a $1,000 margin controls ~$50,000 notional. The +10.4% move to $939.86 yields approximately +$5,200 profit (520% return on margin). However, the same position would face liquidation with as little as a 2% adverse move, so entries near resistance at $941.72 carry meaningful reversal risk.

Short squeeze risk: Traders holding short CFDs with leverage above 20x who entered below $860 face margin calls near current levels. The intraday low-to-high spread of $90.73 means even 10x short positions opened at $900 are deep underwater.

Volatility context: Post-earnings gaps often retrace 30–50% intraday. Monitor whether LLY holds above the $900 level — a close below would suggest a gap-fill trade setup. Check live funding rates on CoinUnited.io before initiating overnight leveraged positions.

Cross-Market Impact

Novo Nordisk A/S faces direct competitive pressure as Mounjaro/Zepbound take further share from Ozempic and Wegovy. NVO CFD traders should anticipate bearish spillover. AbbVie Inc. and Merck & Co., Inc. see mixed signals — Lilly's pricing power intact reinforces broad pharma confidence, but also raises the competitive bar.

At the index level, LLY's heavy weighting in the S&P 500 Index and Dow Jones Industrial Average Index means today's +9.94% surge contributes meaningfully to index-level gains. Healthcare is typically a defensive sector (LLY beta ~0.55), so this beat also reinforces the soft-landing narrative without triggering risk-off rotation.

This event is largely equity-specific with limited direct commodity or forex impact, though drug pricing power intact marginally reduces disinflation expectations — a subtle headwind for rate-cut bets.

Trading Considerations

Key levels: immediate resistance at the intraday high of $941.72; first support at the psychological $900 level, then the day's open near $850.99. The valuation remains stretched at ~51x forward earnings and 13.8x EV/Sales, meaning any macro deterioration or supply-ramp disappointment could trigger sharp de-leveraging. Traders exploring the diversified sector earnings beat wave should also watch healthcare ETF (XLV) volume confirmation before adding exposure. Execution risk on tirzepatide capacity expansion remains the key medium-term variable to monitor.

Trade Eli Lilly and Company on CoinUnited.io

Trade LLY with up to 800xx leverage → | Create Free Account